Back to search
FDAFDA · Food and drugs·Recall number D-1174-2018

AvKARE Valsartan and Hydrochlorothiazide 160 mg/12.5 mg tablets, 90-count bottle, Rx Only, Manufactured for: AvKARE, Inc. Pulaski, TN 38478, NDC 42291-885-90

Published September 12, 2018 · Recall initiated: July 18, 2018

Summary

FDA records drug Class II recall D-1174-2018, published September 12, 2018 and initiated July 18, 2018. Recalling firm: Avkare Incorporated; Status: Terminated; Reported quantity: 24796 bottles; Lot: Lots: 17325 Exp. 09/2018; 17856 Exp. 09/2018; 18396 Exp. 09/2018; 18702 Exp. 02/2019; 19020 Exp. 02/2019; 19222 Exp. 02/2019; 20030 Exp. 04/2019; 20381 Exp. 04/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Avkare Incorporated
Distributor
Nationwide
Lot
Lots: 17325 Exp. 09/2018; 17856 Exp. 09/2018; 18396 Exp. 09/2018; 18702 Exp. 02/2019; 19020 Exp. 02/2019; 19222 Exp. 02/2019; 20030 Exp. 04/2019; 20381 Exp. 04/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was AvKARE Valsartan and Hydrochlorothiazide 160 mg/12.5 mg tablets, 90-count bottle, Rx Only, Manufactured for: AvKARE, Inc. Pulaski, TN 38478, NDC 42291-885-90 recalled?

Yes. FDA published recall D-1174-2018 on September 12, 2018. Reported hazard: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter